Archived Insight | May 26, 2020

University Business Article on Pandemic and Higher Education

In an article from University Business, Segal's Scott Nostaja gives insight on what issues leaders in higher ed may be grappling with as they steer their institutions into a post-pandemic future.

Read the article.

Questions about this story?

Get in touch with our media team for answers.

Key points from this article

The University Business article provides a high-level look at how institutions of higher education have grappled with the COVID-19 crisis, including:

The priorities of higher ed when the crisis first began unfolding
Why decision-makers have found it difficult to pivot to more long-term, strategic planning about the future
What these same leaders should be doing now to help secure their institution's future

Learn more from our insights

Asian Mid Adult Woman Businesswoman Discussing Ideas During Business Meeting

Why Now Is the Right Time for Hybrid Retirement Plans

Hybrid retirement plan designs like variable annuity pension plans (VAPPs) are gaining traction with employers for talent retention and cost control.

Consulting Innovation, Higher Education, Healthcare Industry, Retirement, Investment, Corporate

Read Full Insight

Nurses Taking Patient To An Emergency Room

Some 2026 Projected Health Plan Cost Trends at 10-Year Highs

Segal’s 2026 Health Plan Cost Trend Survey findings help plan sponsors anticipate and manage soaring medical and prescription drug healthcare costs.

Health, Healthcare Industry, Higher Education, Multiemployer Plans, Architecture Engineering & Construction, Public Sector, Pharmaceutical, Corporate

Get the Report

Nurse Attending To An Asian Man In The Waiting Room

Segal Survey Predicts 2026 Healthcare Costs Will Soar Due to Weight-Loss Drugs and Inflation

Segal's 2026 Health Plan Cost Trend Survey report reveals what’s driving medical and Rx drug plan costs.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

Explore all COVID-19 information

We're regularly publishing information on the coronavirus as the situation changes.

Learn More

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.